Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of beclometasone dipropionate (a corticosteroid with anti-inflammatory and vasoconstrictive effects) and propranolol (a nonselective beta-adrenergic receptor antagonist). The interaction between these two drugs is clinically significant as beclometasone dipropionate may reduce the effects of propranolol in lowering blood pressure. Beclometasone works primarily in the lungs to improve lung function and decrease airway hyper-reactivity in conditions like asthma, while propranolol blocks beta-adrenergic receptors leading to effects such as reduced heart rate and blood pressure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on beclometasone dipropionate + propranolol.